British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in cancer treatments. The acquisition significantly strengthens GSK's focus on oncology and its presence in the United States. Nuvalent's promising lung cancer therapies are now part of GSK's portfolio. These treatments are expected to be launched soon if approved by regulators.